Brain Cancer Clinical Trials
Here are the 6 most popular medical studies for brain cancer
Tyrosine Kinase Inhibitor
Lapatinib Before Surgery for Brain Tumor
This trial is testing how well lapatinib ditosylate works in treating patients with high-grade glioma that has come back. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Popular filter options for brain cancer trials
Metastatic Brain Cancer Clinical Trials
View 97 metastatic brain cancer medical studies.
Dendritic cell immunotherapy
Immunotherapy with DCVax-L for Brain Cancer
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Nonsteroidal Anti-inflammatory Drug
Meclofenamate for Brain Cancer
This trial is testing a drug to see if it can prevent brain metastasis growth. This is the first time the drug is being used to treat brain metastasis, and researchers want to see if it's effective and safe.
Phase 3 Brain Cancer Clinical Trials
View 97 phase 3 brain cancer medical studies.
Dendritic cell immunotherapy
Immunotherapy with DCVax-L for Brain Cancer
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
Radiation
Stereotactic Radiosurgery vs. HA-WBRT + Memantine for Brain Cancer
This trial is testing whether memantine used in combination with HA-WBRT helps to improve mental function (measured by how well patients can remember things) compared to those who receive HA-WBRT alone.
Radiation Therapy
Whole Brain Radiotherapy + Stereotactic Radiosurgery for Brain Metastasis
This trial is testing whether adding whole brain radiation therapy with hippocampal avoidance (to protect memory) and memantine (to protect thinking) to standard stereotactic radiosurgery (a high dose of radiation only to the small areas of cancer in the brain) is more effective than stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery.
NMDA receptor antagonist
Memantine for Brain Tumor
This trial compares memantine to usual treatment in treating patients with brain tumors. Memantine may improve cognitive function in children and adolescents receiving brain radiation therapy to treat a primary brain tumor.
View More Brain Cancer Trials
See another 70 medical studies focused on brain cancer.
Frequently Asked Questions
Introduction to brain cancer
What are the top hospitals conducting brain cancer research?
When it comes to cutting-edge research on brain cancer, several hospitals across the United States are making significant strides. Memorial Sloan Kettering Cancer Center in New york leads the charge with 12 active clinical trials dedicated to brain cancer and a total of 52 completed trials since their first recorded trial in 2003. In Tampa, Moffitt Cancer Center is also at the forefront of brain cancer research, currently conducting nine ongoing clinical trials and having completed 22 studies since their inaugural trial in 2004.
Meanwhile, in Boston's prestigious Dana-Farber Cancer Institute, researchers are actively engaged in nine clinical trials focused on brain cancer. Their commitment extends beyond just current investigations; they have conducted a total of 31 studies since initiating their first trial back in 2002. Wake Forest University Health Sciences in Winston-Salem is another institution that has made significant contributions to advancing our understanding of brain cancer. With eight active trials and a total of sixteen previous studies dating back to their initial trial in 2004, they play an important role within this field.
In Urbana's Carle Cancer Center, while smaller-scale by comparison, researchers are making meaningful progress with six active clinical trials for brain cancer and fourteen completed trials thus far. Their journey started only eighteen years ago when they conducted their first recorded trial focusing on this complex condition.
These hospitals represent beacons of hope for those affected by brain cancer — places where innovative minds come together to unravel its mysteries through rigorous scientific exploration. By pushing boundaries and continuously endeavoring for breakthroughs, these institutions bring us closer to improved treatments and better outcomes for patients worldwide who bravely face this challenging disease every day
Which are the best cities for brain cancer clinical trials?
When it comes to brain cancer clinical trials, several cities emerge as top destinations for cutting-edge research. New york, with 39 active trials, Boston with 34 ongoing studies, and Los Angeles with 23 investigations offer promising opportunities for patients seeking innovative treatments. Additionally, Houston's contributions cannot be overlooked as it hosts 22 active trials focused on glioblastoma multiforme and other potential breakthroughs. Atlanta also presents a significant presence in the field of brain cancer research with its 20 ongoing studies. These cities provide individuals battling brain cancer access to groundbreaking clinical trials that pave the way for advancements in care and hope for improved outcomes.
Which are the top treatments for brain cancer being explored in clinical trials?
Exciting developments are underway in clinical trials as researchers explore new treatments for brain cancer. Nivolumab takes the lead with four active trials and 19 all-time brain cancer trials since its introduction in 2014. Similarly, a pharmacological study shows promise with four ongoing trials and 16 all-time brain cancer trials starting in 2003. Pembrolizumab follows closely behind, involved in three active trials and accumulating an impressive total of 17 all-time brain cancer studies since its listing in 2015. Rounding off the top contenders is stereotactic radiosurgery, currently being tested in three active trials and boasting an extensive history of involvement with a remarkable 37 all-time brain cancer studies dating back to 2004. These advancements offer hope for improved outcomes and brighter futures for patients battling this complex disease.
What are the most recent clinical trials for brain cancer?
Promising advancements are underway in the field of brain cancer research, with recent clinical trials offering hope for patients. One such trial focuses on NovoTTF-200A, a cutting-edge treatment that has progressed to Phase 1 and Phase 2 trials. Another study explores the potential benefits of RRx-001, currently in Phase 1 testing. Additionally, PET/CT and MRI imaging play crucial roles in a Phase 2 trial aimed at enhancing diagnostic capabilities for brain cancer. Furthermore, ongoing investigations into Nivolumab's efficacy through Phase 2 studies demonstrate continued efforts to improve treatment options for this challenging disease. These recent clinical trials signal encouraging progress in the fight against brain cancer and inspire optimism for better outcomes in the future
What brain cancer clinical trials were recently completed?
Recent advancements in brain cancer research have brought about the completion of several noteworthy clinical trials. In October 2020, a trial conducted by Blue Earth Diagnostics explored the potential of 18F fluciclovine as a diagnostic tool for brain cancer. Another trial involving the same sponsor and treatment was completed in August 2020, further contributing to our understanding of its efficacy. Emory University's investigation into WP1066 concluded in May 2020, shedding light on potential therapeutic options for this complex disease. These significant milestones underscore the tireless efforts of researchers striving to find improved treatments and diagnostics for individuals affected by brain cancer.